SRR8942991
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.410
- ANGIOGENESIS+0.390
- KRAS_SIGNALING_UP+0.350
- TGF_BETA_SIGNALING+0.300
- ANDROGEN_RESPONSE+0.230
- KRAS_SIGNALING_DN+0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
- COAGULATION+0.210
- INFLAMMATORY_RESPONSE+0.210
- APICAL_SURFACE+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.530
- DNA_REPAIR-0.490
- OXIDATIVE_PHOSPHORYLATION-0.480
- MYC_TARGETS_V1-0.430
- INTERFERON_ALPHA_RESPONSE-0.420
- UNFOLDED_PROTEIN_RESPONSE-0.410
- MITOTIC_SPINDLE-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02193 | — | cohortA1 | 0.890 |
| 2 | TCGA-55-8096-01A-11R-2241-07 | — | cohortA1 | 0.884 |
| 3 | 37cb9185-9334-45cc-8afe-6aea6784aaba | — | — | 0.882 |
| 4 | 15-109pB4_FFPE | — | — | 0.877 |
| 5 | R352 | — | — | 0.872 |
| 6 | 4108a871-c064-4537-9331-e59798d7d492 | — | — | 0.866 |
| 7 | C3L-03268 | — | cohortA1 | 0.863 |
| 8 | TCGA-G2-A2EC-01A-11R-A180-07 | — | — | 0.862 |
| 9 | 20030069.LumA | — | A | 0.858 |
| 10 | TCGA-CR-7388-01A-11R-2016-07 | — | — | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.410 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |